From: Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Mean +/- STD | |||||||||
---|---|---|---|---|---|---|---|---|---|
Marker | Responders | Non-responders | Delta | t-statistic | p-value | ||||
MVA | 10.3 | +/- | 9.7 | 5.6 | +/- | 4.2 | 4.7 | 2.847 | 0.0055 |
VEGF | 33.4 | +/- | 11.2 | 38 | +/- | 10.9 | -4.6 | -1.548 | 0.125 |
VEGF-R1 | 32.4 | +/- | 7.6 | 33 | +/- | 8.2 | -0.6 | -0.288 | 0.7739 |
VEGF-R2 | 31.4 | +/- | 8.3 | 33.4 | +/- | 8.0 | -2 | -0.929 | 0.3554 |
VEGF-R3 | 48.3 | +/- | 13.3 | 50.9 | +/- | 10.2 | -2.6 | -0.879 | 0.3817 |
c-RAF | 35.1 | +/- | 14.9 | 34.4 | +/- | 13.5 | 0.7 | -0.177 | 0.8601 |
B-RAF | 39.5 | +/- | 12.8 | 42 | +/- | 14.1 | -2.5 | -0.707 | 0.4813 |
c-Kit | 44.0 | +/- | 12.8 | 43.8 | +/- | 12.4 | 0.2 | -0.047 | 0.9629 |
PDGFR-β | 37.5 | +/- | 14.9 | 33.6 | +/- | 9.5 | 3.9 | -1.321 | 0.1897 |